TATVA Tatva Chintan Pharma Chem Q4 FY26 results (Jan–Mar 2026) and concall
Tatva Chintan delivered strong Q4 FY26 results with significant revenue and EBITDA growth, driven by improved product mix and operating leverage. The Electrolyte Salts segment was a standout performer, while new product commercialization in Pharma and Semiconductor Chemicals is set to drive future growth. The company is also advancing its major Jolva greenfield expansion, though it faced some production challenges in the PASC segment and navigated raw material price volatility.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 24.1%, net profit up 900.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 86 | 108 | 117 | 124 | 131 +52% | 134 +24% |
| EBITDA | 7 | 9 | 17 | 22 | 25 +257% | 28 +211% |
| Net profit | 0 | 1 | 7 | 10 | 15 | 10 +900% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
